Loading…
← CockpitCompetitor Analysis › EBO.AX EBOS Group LimitedOpen in the cockpit ↗

EBOS Group LimitedEBO.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Medical Specialties
Momentum strong 65
Mkt cap
$2.50B
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$1.25M
20-day average traded
Fwd P/E
15.7×
forward earnings
ROIC−WACC
-0.6 pp
WACC 6.4%
Hurdle
-2 pp
Req g minus delivered
Next earnings
97 days
23 Feb 2027
Close · AUDA$17.85
1D-0.8%
1W+1.5%
1M+9.8%
3M-5.8%
6M+7.1%
YTD-24.5%
1Y-29.2%
ATR %2.4%
52w lowhigh30.3% off high

What EBOS does

Employees: 6,200

EBOS at a glance

Size EBOS (EBO.AX) is an Australia Health Care company (Medical Specialties) with a market value of $2.50B, the 105th largest of 317 Australia companies the cockpit tracks. Shares closed at A$17.85 on 18 Nov 2026.

Performance Over six months the shares gained 7.1%, against -1.3% for the median peer and +1.2% for the Australia market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 3.1% over the last twelve months (peer median +5.1%); the operating margin is 2.8% (peer median 8.3%).

Valuation It trades at 15.7× forward earnings against a peer median of 24.3× (5th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -2 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.6 points below its cost of capital (6.4% WACC).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012021 May 202621 Aug 202618 Nov 2026EBO.AX 111Peer median 100
Six months, rebased to 100: EBOS against the median of its 20 peers (local-currency closes).

EBOS financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$12.8BA$12.8BA$12.5BA$13.0BA$12.3B
Revenue growth—+3%-4%+6%—
Gross profitA$911MA$909MA$935MA$945MA$921M
EBITDAA$532MA$530MA$550MA$605MA$574M
Net incomeA$214MA$214MA$218MA$268MA$255M
Free cash flowA$214MA$207MA$298MA$249MA$299M
Capital expenditureA$144MA$139MA$148MA$117MA$99.0M
Total debtn/aA$1.89BA$1.62BA$1.65BA$1.28B

Quarterly statements and history in the cockpit →

EBOS competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%MOVE002901NEOGOBCK300529EKTA-B688029CELC2276COTNATRCMETNDRW86951ESTAVCYTBONEX688114AFXIRTCEBO.AX6-month return →1-month return →
Up and to the right = strong over both horizons. EBOS is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%0×100×200×MOVE002901NEOGOBCK300529EKTA-BCOTNATRCMETNDRW86951VCYTBONEXAFXIRTCEBO.AXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. EBOS is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%002901OBCK300529EKTA-B6880292276ATRCDRW86951VCYTBONEX688114AFXIRTCEBO.AXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. EBOS is the large dot.

EBOS competitors and peer comparison

How EBOS compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

EBOS against its 20 peers (data as of 18 Nov 2026)
MeasureEBO.AXPeer medianRank in peer set
1-month return+9.8%-4.1%6th highest of 21
6-month return+7.1%-1.3%7th highest of 21
Distance from 52-week high-30.3%-27.0%10th lowest of 21
Revenue growth (TTM)+3.1%+5.1%9th lowest of 20
Operating margin2.8%8.3%5th lowest of 20
Forward P/E15.7×24.3×5th cheapest of 18
Growth the price implies (Req g, 7 yrs)4.7%12.2%4th least demanding of 15
Growth delivered (Del g)+6.8%+10.6%5th lowest of 15
Hurdle (Req g minus delivered)-2.2 pp-0.5 pp8th least demanding of 15
ROIC minus cost of capital-0.6 pp-0.7 pp10th highest of 20
Net debt / EBITDA3.1×0.4×2nd most indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
EBOS EBO.AXAustralia$2.50B+7%+3%3%15.7×4.7%+6.8%
Medacta MOVE.SWSwitzerland$2.48B-28%+8%15%24.0×n/an/a
Double Medical Technology 002901.SZChina$2.43B-2%+13%26%24.2×7.6%+10.4%
Neogen NEOGUnited States$2.42B+25%0%0%32.6×n/an/a
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%12.3×-1.2%+8.0%
Jafron Biomedical 300529.SZChina$2.35B+3%+1%37%24.3×6.1%+0.6%
Elekta EKTA-B.STSweden$2.35B0%-7%6%15.3×10.7%+4.0%
Micro-Tech (Nanjing) 688029.SSChina$2.33B0%+6%18%28.1×11.9%+19.2%
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
Shanghai Conant Optical 2276.HKHong Kong$2.25B-17%+8%29%22.1×-1.1%+14.1%
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
Metall Zug METN.SWSwitzerland$2.19B+20%0%-10%139.8×n/an/a
Draegerwerk AG & Co. KGaA DRW8.DEGermany$2.13B+25%+5%7%10.2×-10.2%+0.4%
JEOL 6951.TJapan$2.12B-2%-15%12%15.5×22.2%+10.2%
Establishment Labs ESTAUnited States$2.11B+1%+38%-7%n/an/an/a
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%

Questions

Which companies are EBOS's closest peers?
The cockpit's peer set: Medacta (MOVE.SW), Double Medical Technology (002901.SZ), Neogen (NEOG), Ottobock SE & Co. KGaA (OBCK.DE), Jafron Biomedical (300529.SZ), Elekta (EKTA-B.ST), Micro-Tech (Nanjing) (688029.SS), Celcuity (CELC).
Is EBOS expensive compared with its peers?
On forward p/e it trades at 15.7× against a peer median of 24.3×, 5th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -2 pp: the price already allows for a slowdown.
How has EBOS stock performed?
Over six months to 18 Nov 2026 the shares returned +7.1% against -1.3% for the median peer; over one year -29.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.